Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lazonail is a topical botanical gel developed by Hartington Pharmaceuticals for nail care and the treatment of conditions such as onychomycosis (nail fungal infection). The formulation is 94% natural and plant-based, containing walnut extract and a blend of minerals including calcium, zinc, iron, and magnesium. It is designed to revitalize, nourish, and moisturize nails damaged by manicures, gel polish, acrylics, or chemical exposure, providing a significant increase in nail hardness and shine. The gel is formulated for rapid absorption and can be applied to both bare and varnished nails. Clinical data from the manufacturer suggests a 10% increase in nail hardness after the first application and visible improvements in nail strength within seven days.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lazonail.